These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 33761302)

  • 1. Latent Tuberculosis: Two Centuries of Confusion.
    Behr MA; Kaufmann E; Duffin J; Edelstein PH; Ramakrishnan L
    Am J Respir Crit Care Med; 2021 Jul; 204(2):142-148. PubMed ID: 33761302
    [No Abstract]   [Full Text] [Related]  

  • 2. Tolerability of rifampin monotherapy for latent tuberculosis infection in children.
    Daskalaki I; Byun J; Dogbey MC; Tolbert-Warren C; Watson BM
    Pediatr Infect Dis J; 2011 Nov; 30(11):1014-5. PubMed ID: 21997666
    [No Abstract]   [Full Text] [Related]  

  • 3. Tuberculosis, drug resistance, and the history of modern medicine.
    Keshavjee S; Farmer PE
    N Engl J Med; 2012 Sep; 367(10):931-6. PubMed ID: 22931261
    [No Abstract]   [Full Text] [Related]  

  • 4. Influence of County Sampling on Past Estimates of Latent Tuberculosis Infection Prevalence.
    Haddad MB; Raz KM; Hill AN; Navin TR; Winston CA; Castro KG; Gandhi NR; Lash TL
    Ann Am Thorac Soc; 2019 Aug; 16(8):1069-1071. PubMed ID: 30888833
    [No Abstract]   [Full Text] [Related]  

  • 5. Professor D A Mitchison: 60 years of contributions to the chemotherapy of tuberculosis.
    Butcher PD; Jindani A
    Tuberculosis (Edinb); 2010 May; 90(3):160-1. PubMed ID: 20382087
    [No Abstract]   [Full Text] [Related]  

  • 6. Tuberculosis.
    Kelly AM
    Nurs Clin North Am; 2019 Jun; 54(2):193-205. PubMed ID: 31027661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simple Estimates for Local Prevalence of Latent Tuberculosis Infection, United States, 2011-2015.
    Haddad MB; Raz KM; Lash TL; Hill AN; Kammerer JS; Winston CA; Castro KG; Gandhi NR; Navin TR
    Emerg Infect Dis; 2018 Oct; 24(10):1930-1933. PubMed ID: 30226174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Taming tuberculosis: a challenge for science and society.
    Nathan C
    Cell Host Microbe; 2009 Mar; 5(3):220-4. PubMed ID: 19286131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How to kill dormant
    Kaprelyants AS; Salina EG; Makarov VA
    Int J Mycobacteriol; 2018; 7(4):399-400. PubMed ID: 30531045
    [No Abstract]   [Full Text] [Related]  

  • 10. Latent Mycobacterium tuberculosis infection.
    Getahun H; Matteelli A; Chaisson RE; Raviglione M
    N Engl J Med; 2015 May; 372(22):2127-35. PubMed ID: 26017823
    [No Abstract]   [Full Text] [Related]  

  • 11. [Clinical and experimental pharmacology as a basis for the strategy and tactics of tuberculosis chemotherapy (1970-2008)].
    Sokolova GB
    Tuberk Biolezni Legkih; 2009; (12):22-7. PubMed ID: 20099385
    [No Abstract]   [Full Text] [Related]  

  • 12. Mycobacterium tuberculosis strain 18b, a useful non-virulent streptomycin dependent mutant to study latent tuberculosis as well as for in vivo and in vitro testing of anti-tuberculosis drugs.
    Campos-Neto A
    Tuberculosis (Edinb); 2016 Jul; 99():54-55. PubMed ID: 27450005
    [No Abstract]   [Full Text] [Related]  

  • 13. Focus on latent tuberculosis.
    The Lancet Respiratory Medicine
    Lancet Respir Med; 2016 Oct; 4(10):763. PubMed ID: 27707455
    [No Abstract]   [Full Text] [Related]  

  • 14. New tactics against tuberculosis.
    Barry CE; Cheung MS
    Sci Am; 2009 Mar; 300(3):62-9. PubMed ID: 19253775
    [No Abstract]   [Full Text] [Related]  

  • 15. Lessons from seven decades of antituberculosis drug discovery.
    Barry CE
    Curr Top Med Chem; 2011; 11(10):1216-25. PubMed ID: 21401509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Policy Implications of Mathematical Modeling of Latent Tuberculosis Infection Testing and Treatment Strategies to Accelerate Tuberculosis Elimination.
    Marks SM; Dowdy DW; Menzies NA; Shete PB; Salomon JA; Parriott A; Shrestha S; Flood J; Hill AN
    Public Health Rep; 2020; 135(1_suppl):38S-43S. PubMed ID: 32735183
    [No Abstract]   [Full Text] [Related]  

  • 17. New 1-hydroxy-2-thiopyridine derivatives active against both replicating and dormant Mycobacterium tuberculosis.
    Salina EG; Ryabova O; Vocat A; Nikonenko B; Cole ST; Makarov V
    J Infect Chemother; 2017 Nov; 23(11):794-797. PubMed ID: 28527650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Present-day treatment of tuberculosis and latent tuberculosis infection.
    Pérez-Camacho I; Rivero-Juárez A; Kindelán JM; Rivero A
    Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 1():41-6. PubMed ID: 21420566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Better data to drive more effective care for people with latent tuberculosis infection in Canada.
    Essue BM; Milinkovic D; Birch S
    CMAJ; 2018 Jun; 190(23):E700-E701. PubMed ID: 29891473
    [No Abstract]   [Full Text] [Related]  

  • 20. A brief history of tuberculosis in Iran during the 19th and 20th centuries.
    Azizi MH; Bahadori M
    Arch Iran Med; 2011 May; 14(3):215-9. PubMed ID: 21529117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.